Indoco Remedies Limited (INDOCO.NS)
INR 230.81
(2.86%)
INR 230.81
(2.86%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 8.04 Billion INR | -28.11% |
| 2022 | 11.18 Billion INR | 7.58% |
| 2021 | 10.39 Billion INR | 21.07% |
| 2020 | 8.58 Billion INR | 15.31% |
| 2019 | 7.44 Billion INR | 20.45% |
| 2018 | 6.18 Billion INR | -7.23% |
| 2017 | 6.66 Billion INR | -6.21% |
| 2016 | 7.1 Billion INR | 12.42% |
| 2015 | 6.32 Billion INR | 13.61% |
| 2014 | 5.56 Billion INR | 20.82% |
| 2013 | 4.6 Billion INR | 25.02% |
| 2012 | 3.68 Billion INR | 31.03% |
| 2011 | 2.81 Billion INR | 3.98% |
| 2010 | 2.7 Billion INR | -32.11% |
| 2009 | 3.98 Billion INR | 51.62% |
| 2008 | 2.62 Billion INR | 0.0% |
| 2007 | - INR | -100.0% |
| 2006 | 3.25 Billion INR | 33.92% |
| 2005 | 2.43 Billion INR | 25.38% |
| 2004 | 1.94 Billion INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.93 Billion INR | 5.41% |
| 2024 Q1 | 1.65 Billion INR | -14.94% |
| 2023 Q2 | 3.26 Billion INR | 13.24% |
| 2023 Q4 | 1.94 Billion INR | -38.62% |
| 2023 Q3 | 3.16 Billion INR | -3.02% |
| 2023 FY | 8.04 Billion INR | -28.11% |
| 2023 Q1 | 2.88 Billion INR | -3.08% |
| 2022 Q2 | 2.77 Billion INR | 5.49% |
| 2022 Q1 | 2.63 Billion INR | 0.4% |
| 2022 FY | 11.18 Billion INR | 7.58% |
| 2022 Q4 | 2.97 Billion INR | 5.87% |
| 2022 Q3 | 2.8 Billion INR | 1.17% |
| 2021 Q2 | 2.66 Billion INR | -1.67% |
| 2021 Q1 | 2.71 Billion INR | 34.46% |
| 2021 FY | 10.39 Billion INR | 21.07% |
| 2021 Q3 | 2.4 Billion INR | -9.91% |
| 2021 Q4 | 2.62 Billion INR | 9.11% |
| 2020 FY | 8.58 Billion INR | 15.31% |
| 2020 Q2 | 2.32 Billion INR | 25.74% |
| 2020 Q1 | 1.85 Billion INR | -0.48% |
| 2020 Q4 | 2.01 Billion INR | -15.74% |
| 2020 Q3 | 2.39 Billion INR | 2.78% |
| 2019 Q2 | 1.96 Billion INR | 21.69% |
| 2019 FY | 7.44 Billion INR | 20.45% |
| 2019 Q4 | 1.86 Billion INR | -7.26% |
| 2019 Q3 | 2 Billion INR | 2.04% |
| 2019 Q1 | 1.61 Billion INR | 0.67% |
| 2018 FY | 6.18 Billion INR | -7.23% |
| 2018 Q2 | 1.56 Billion INR | 10.73% |
| 2018 Q1 | 1.41 Billion INR | 0.0% |
| 2018 Q3 | 1.59 Billion INR | 2.04% |
| 2018 Q4 | 1.6 Billion INR | 0.4% |
| 2017 FY | 6.66 Billion INR | -6.21% |
| 2016 FY | 7.1 Billion INR | 12.42% |
| 2015 FY | 6.32 Billion INR | 13.61% |
| 2014 Q1 | 1.26 Billion INR | 0.0% |
| 2014 FY | 5.56 Billion INR | 20.82% |
| 2013 FY | 4.6 Billion INR | 25.02% |
| 2013 Q1 | 942.8 Million INR | 34.69% |
| 2012 Q3 | 867.8 Million INR | 0.0% |
| 2012 FY | 3.68 Billion INR | 31.03% |
| 2012 Q4 | 699.96 Million INR | -19.34% |
| 2011 FY | 2.81 Billion INR | 3.98% |
| 2010 FY | 2.7 Billion INR | -32.11% |
| 2009 FY | 3.98 Billion INR | 51.62% |
| 2008 FY | 2.62 Billion INR | 0.0% |
| 2007 FY | - INR | -100.0% |
| 2006 FY | 3.25 Billion INR | 33.92% |
| 2005 FY | 2.43 Billion INR | 25.38% |
| 2004 FY | 1.94 Billion INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 69.967% |
| Hester Biosciences Limited | 1.27 Billion INR | -531.492% |
| Aarti Drugs Limited | 8.31 Billion INR | 3.285% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | -37.927% |
| Albert David Limited | 1.4 Billion INR | -471.201% |
| Alembic Limited | 1 Billion INR | -704.214% |
| Alkem Laboratories Limited | 52.29 Billion INR | 84.621% |
| Bafna Pharmaceuticals Limited | 452.15 Million INR | -1678.823% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -446.471% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.54 Million INR | -64013.193% |
| Brooks Laboratories Limited | 65.62 Million INR | -12156.934% |
| Eris Lifesciences Limited | 10.42 Billion INR | 22.862% |
| FDC Limited | 6.58 Billion INR | -22.119% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 35.309% |
| Gufic Biosciences Limited | 4.07 Billion INR | -97.436% |
| Hikal Limited | 5.95 Billion INR | -34.995% |
| Ind-Swift Limited | 2.17 Billion INR | -270.213% |
| Innova Captab Limited | 3.46 Billion INR | -132.159% |
| IOL Chemicals and Pharmaceuticals Limited | 4.71 Billion INR | -70.435% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -1132.474% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 59.054% |
| Lincoln Pharmaceuticals Limited | 1.88 Billion INR | -326.262% |
| Lupin Limited | 125.09 Billion INR | 93.571% |
| Mangalam Drugs & Organics Limited | 691.19 Million INR | -1063.64% |
| Medico Remedies Limited | 262.14 Million INR | -2968.161% |
| Morepen Laboratories Limited | 6.16 Billion INR | -30.541% |
| Nectar Lifesciences Limited | 4.82 Billion INR | -66.753% |
| Orchid Pharma Limited | 2.32 Billion INR | -246.636% |
| Procter & Gamble Health Limited | 5.78 Billion INR | -39.119% |
| RPG Life Sciences Limited | 2.48 Billion INR | -223.923% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -1196.261% |
| Sigachi Industries Limited | 2 Billion INR | -301.691% |
| Solara Active Pharma Sciences Limited | -1.65 Billion INR | 585.718% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -95.063% |
| Themis Medicare Limited | 2.42 Billion INR | -232.354% |
| Unichem Laboratories Limited | 4.86 Billion INR | -65.326% |
| Vaishali Pharma Limited | 90.32 Million INR | -8804.709% |
| Wanbury Limited | 1.73 Billion INR | -364.741% |
| Windlas Biotech Limited | 1.33 Billion INR | -500.762% |
| ZIM Laboratories Limited | 1.26 Billion INR | -534.4% |
| Ind-Swift Laboratories Limited | 4.13 Billion INR | -94.594% |
| Ipca Laboratories Limited | 48.58 Billion INR | 83.445% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 96.888% |
| Venus Remedies Limited | 2.18 Billion INR | -268.508% |
| Sakar Healthcare Limited | 699.58 Million INR | -1049.682% |
| Aurobindo Pharma Limited | 109.54 Billion INR | 92.658% |
| Divi's Laboratories Limited | 32.44 Billion INR | 75.207% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | -29.253% |
| Mankind Pharma Limited | 42.19 Billion INR | 80.939% |
| Sequent Scientific Limited | 2.97 Billion INR | -170.014% |
| Laurus Labs Limited | 15.44 Billion INR | 47.937% |
| Neuland Laboratories Limited | 8.24 Billion INR | 2.484% |
| J. B. Chemicals & Pharmaceuticals Limited | 15.25 Billion INR | 47.29% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 88.401% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 93.576% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | -284.091% |
| Wockhardt Limited | 7.72 Billion INR | -4.184% |
| Bal Pharma Limited | 770.19 Million INR | -944.281% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 95.084% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -117.647% |
| Par Drugs and Chemicals Limited | 529.13 Million INR | -1420.025% |
| Caplin Point Laboratories Limited | 9.2 Billion INR | 12.638% |
| Shilpa Medicare Limited | 3.56 Billion INR | -125.807% |
| Valiant Laboratories Limited | 138.02 Million INR | -5727.036% |
| Ajanta Pharma Limited | 21.06 Billion INR | 61.816% |
| Aarey Drugs & Pharmaceuticals Limited | 113.02 Million INR | -7015.873% |
| Granules India Limited | 16.79 Billion INR | 52.123% |
| Medicamen Biotech Limited | 495.49 Million INR | -1523.225% |
| Syncom Formulations (India) Limited | 559.5 Million INR | -1337.526% |
| Piramal Enterprises Limited | 8.04 Billion INR | 0.004% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 82.798% |
| NATCO Pharma Limited | 25.73 Billion INR | 68.748% |
| Suven Life Sciences Limited | -200.79 Million INR | 4105.538% |
| Krebs Biochemicals & Industries Limited | -108.74 Million INR | 7496.066% |
| Strides Pharma Science Limited | 14.38 Billion INR | 44.1% |
| Alpa Laboratories Limited | 188.89 Million INR | -4157.921% |
| Lasa Supergenerics Limited | 121.02 Million INR | -6545.46% |
| Sun Pharma Advanced Research Company Limited | 391.06 Million INR | -1956.686% |